Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Medical Oncology
•
Lymphoma
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
Related Questions
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
How would you treat cold agglutinin disease secondary to underlying marginal zone lymphoma with only bone marrow involvement and no disease elsewhere?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
When would you consider using a BTK inhibitor in the frontline setting for lymphoplasmacytic lymphoma (LPL) or Waldenstrom's Macroglobulinemia?
How would you treat an elderly patient with DLBCL with only brain and unilateral testicular involvement?
